Drug intelligence / Profile preview

GK201

Development stage: Phase 1
Lead developer: 苏州国匡医药科技
Modality: Small Molecules
Administration: Oral

Overview

GK201 is an orally bioavailable small molecule CTLA-4 (cytotoxic T-lymphocyte-associated protein 4) degrader and inhibitor developed by Suzhou Guokuang Pharmaceutical Technology. It is designed for the treatment of advanced solid tumors, particularly those with systemic metastasis. As an oral small molecule, GK201 avoids antibody-dependent cellular cytotoxicity (ADCC) and immunogenicity associated with traditional CTLA-4 monoclonal antibodies, potentially offering a superior safety profile with reduced immune-related adverse events (irAEs) while maintaining robust antitumor efficacy.

Targets

CTLA-4 (Cytotoxic t-lymphocyte–associated protein 4)

Beyond the preview

Go deeper on GK201.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on GK201.